Emerging treatments for postmenopausal osteoporosis – focus on denosumab

Código QR

Emerging treatments for postmenopausal osteoporosis – focus on denosumab

Piet GeusensDepartment of Internal Medicine, Subdivision of Rheumatology, Maastricht University Medical Center, Maastricht, The Netherlands and Biomedical Research Institute, University Hasselt, BelgiumAbstract: The pathway of the receptor activator of the nuclear factor κB ligand (RANKL),...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Piet Geusens
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2009
Materias:	RANKL OPG Osteoporosis Rheumatoid arthritis Paget's disease of bone Metastatic bone diseases Geriatrics RC952-954.6
Acceso en línea:	https://doaj.org/article/4cf8c096344043bb8ebe89a9ae1dbba8
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Bone-sparing effects of rituximab and body composition analysis in a cohort of postmenopausal women affected by rheumatoid arthritis – retrospective study
por: Suhel Gabriele Al Khayyat, et al.
Publicado: (2021)

Selective estrogen receptor modulator (SERM) for the treatment of osteoporosis in postmenopausal women: focus on lasofoxifene
por: Luigi Gennari, et al.
Publicado: (2010)

Correlations between bone turnover markers, serum magnesium and bone mass density in postmenopausal osteoporosis
por: Mederle OA, et al.
Publicado: (2018)

Increased Osteoblastic Cxcl9 Contributes to the Uncoupled Bone Formation and Resorption in Postmenopausal Osteoporosis
por: Liu Z, et al.
Publicado: (2020)

Systematic review of raloxifene in postmenopausal Japanese women with osteoporosis or low bone mass (osteopenia)
por: Fujiwara S, et al.
Publicado: (2014)

Relación entre los niveles de compuestos volátiles sulfurados con los niveles de RANKL y OPG en pacientes con periodontitis crónica moderada o severa: Estudio transversal
por: Prieto Damm,D, et al.
Publicado: (2013)

Oral Exposure to ZnO Nanoparticles Disrupt the Structure of Bone in Young Rats via the OPG/RANK/RANKL/IGF-1 Pathway
por: Xu X, et al.
Publicado: (2020)

Analysis of three-dimensional bone mineral density and bone strength measured by quantitative computed tomography following denosumab discontinuation in a patient with postmenopausal osteoporosis
por: Tsuchiya K, et al.
Publicado: (2019)

Effects of dexamethasone, celecoxib, and methotrexate on the histology and metabolism of bone tissue in healthy Sprague Dawley rats
por: Liu YZ, et al.
Publicado: (2015)

Osteoporosis in men: epidemiology and treatment with denosumab
por: Sidlauskas KM, et al.
Publicado: (2014)

Prevalence and Risk Factors of Osteoporosis in Chinese Postmenopausal Women Awaiting Total Knee Arthroplasty
por: Tao Y, et al.
Publicado: (2021)

Effects of annatto-derived tocotrienol supplementation on osteoporosis induced by testosterone deficiency in rats
por: Chin KY, et al.
Publicado: (2014)

Relationship between abnormal glucose metabolism and osteoporosis in Han Chinese men over the age of 50 years
por: Liu M, et al.
Publicado: (2019)

Management of bone metastases in refractory prostate cancer – role of denosumab
por: Paller CJ, et al.
Publicado: (2012)

Osteoporosis international a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA.
Publicado: (1990)

Menatetrenone versus alfacalcidol in the treatment of Chinese postmenopausal women with osteoporosis: a multicenter, randomized, double-blinded, double-dummy, positive drug-controlled clinical trial
por: Jiang Y, et al.
Publicado: (2014)

Eldecalcitol for the treatment of osteoporosis
por: Noguchi Y, et al.
Publicado: (2013)

Novel insights into the relationship between nonalcoholic fatty liver disease and osteoporosis
por: Filip R, et al.
Publicado: (2018)

Anatase and Rutile TiO2 Nanoparticles Lead Effective Bone Damage in Young Rat Model via the IGF-1 Signaling Pathway
por: Cheng W, et al.
Publicado: (2021)

Reducing hip fracture risk with risedronate in elderly women with established osteoporosis
por: Tahir Masud, et al.
Publicado: (2009)

Hip fracture protection by alendronate treatment in postmenopausal women with osteoporosis: a review of the literature
por: Jun Iwamoto, et al.
Publicado: (2008)

The epidemiology and management of postmenopausal osteoporosis: a viewpoint from Brazil
por: Baccaro LF, et al.
Publicado: (2015)

BFH-OSTM, a new predictive screening tool for identifying osteoporosis in elderly Han Chinese males
por: Lin J, et al.
Publicado: (2017)

Receptor activator of nuclear factor-κB ligand and osteoprotegerin: maintaining the balance to prevent bone loss
por: Anne-Priscille Trouvin, et al.
Publicado: (2010)

Pharmacological Therapy of Osteoporosis: What’s New?
por: Iolascon G, et al.
Publicado: (2020)

Is grand multiparity a risk factor for the development of postmenopausal osteoporosis?
por: Peker N, et al.
Publicado: (2018)

High bone turnover status as a risk factor in symptomatic hypocalcemia following denosumab treatment in a male patient with osteoporosis
por: Ishikawa K, et al.
Publicado: (2018)

Response to teriparatide in Chinese patients with established osteoporosis: osteocalcin and lumbar spine bone-mineral density changes from teriparatide Phase III study
por: Lu C, et al.
Publicado: (2017)

Efficacy and safety of bazedoxifene for postmenopausal osteoporosis
por: Kawate H, et al.
Publicado: (2011)

BFH-OST, a new predictive screening tool for identifying osteoporosis in postmenopausal Han Chinese women
por: Ma Z, et al.
Publicado: (2016)

New Generation of Meso and Antiprogestins (SPRMs) into the Osteoporosis Approach
por: Magdalena Woźniczka, et al.
Publicado: (2021)

Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis
por: Paula Rackoff
Publicado: (2009)

Effects of age, sex, and ethnicity on bone health status of the elderly in Kuala Lumpur, Malaysia
por: Chin KY, et al.
Publicado: (2016)

Integrative Bone Metabolomics—Lipidomics Strategy for Pathological Mechanism of Postmenopausal Osteoporosis Mouse Model
por: Hongxia Zhao, et al.
Publicado: (2018)

Changes in microarchitectural characteristics at the tibial epiphysis induced by collagen-induced rheumatoid arthritis over time
por: Lee JH, et al.
Publicado: (2012)

Alendronate improves QOL of postmenopausal women with osteoporosis
por: Hisaya Kawate, et al.
Publicado: (2010)

Muscular strength measurements indicate bone mineral density loss in postmenopausal women
por: Zhou Z, et al.
Publicado: (2013)

Correlation between bone mineral density and serum trace elements in response to supervised aerobic training in older adults
por: Alghadir AH, et al.
Publicado: (2016)

Lactobacillus helveticus (ATCC 27558) upregulates Runx2 and Bmp2 and modulates bone mineral density in ovariectomy-induced bone loss rats
por: Parvaneh M, et al.
Publicado: (2018)

Validation of three tools for identifying painful new osteoporotic vertebral fractures in older Chinese men: bone mineral density, Osteoporosis Self-Assessment Tool for Asians, and fracture risk assessment tool
por: Lin JS, et al.
Publicado: (2016)